OnconexLung Cancer (Somatic)

Lung cancer is the leading cause of global cancer incidence and mortality, accounting for an estimated 2 million diagnoses and 1.8 million deaths. For diagnosis, lung cancers are classified into two main histological types - small cell lung cancer ( SCLC ) and non-small cell lung cancer (NSCLC), that are based on the appearance of the neoplastic cells under a microscope. NSCLC accounts for more than 80% of all lung cancer cases and includes non-squamous cell carcinoma- large-cell carcinoma and adenocarcinoma, and squamous cell carcinoma.

Molecular biomarker testing of NSCLC is considered standard of care and part of the diagnostic algorithm to identify subsets of patients for molecular-targeted treatment. Epidermal growth factor receptor (EGFR) - activating mutations, one of the most commonly mutated genes in NSCLC, are harboured by up to 15% of lung adenocarcinoma and less than 5% of squamous cell carcinomas (SCC).

NGS enables massively parallel sequencing for a large number of genes with accurate reads while being relatively inexpensive.

Clinical Utility:

• Identify Driver Mutations - mutation in the DNA Sequence that cause cells to become cancers, grow & spread in body.
• Drug profiling for Chemotherapy & Targeted Drugs.
• Predictive genomic biomarker identification to guide the therapeutic process.
• The targeted NGS panel offers wide coverage and in-depth analysis to detect the known and novel variants.
• The multigene approach reduces the time for diagnosis providing a more economical solution.

Panel Covered:

• Comprehensive genomic profiling for 100 cancer genes associated with lung cancers.
• Screening for clinically significant genes based on National Comprehensive Cancer Network (NCCN) guidelines.
• Genetic counselling to guide through the report and discuss the available management & treatment options in case of clinical findings.
• Reporting - Pathogenic and Likely Pathogenic Variants are reported following the ACMG recommended guidelines.
• Best in class Bioinformatics pipeline for the most accurate analysis by our experienced Bioinformatics team.

Who Should Get Tested?

• Patients diagnosed with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) seeking personalized treatment options.
• Individuals with a family history of lung cancers.
• Patients with EGFR activating mutations and other genetic aberrations.
• Clinicians looking for comprehensive genomic profiling to inform targeted therapies.

What Does the Report Tell Me?

The OnconexLung Cancer (Somatic) test report provides detailed insights into the genetic mutations driving lung cancers. It identifies driver mutations, informs drug profiling for chemotherapy and targeted drugs, and highlights predictive genomic biomarkers to guide the therapeutic process. The report includes pathogenic and likely pathogenic variants following ACMG guidelines, offering a clear understanding of the molecular underpinnings of the tumor and potential treatment options.

Next Steps Post Getting the Report:

After receiving the OnconexLung Cancer (Somatic) test report, the following steps are recommended:

• Schedule a genetic counseling session to interpret the results and discuss available management and treatment options.
• Discuss the report with your healthcare provider to tailor the treatment plan based on the genetic profile of the tumor.
• Consider targeted therapies and other personalized treatment options informed by the genomic insights provided in the report.
• Utilize the free genetic counseling offered to navigate the results, explore therapeutic strategies, and make informed decisions about your treatment plan.

Note: Pre-test & post-test genetic counseling can be provided. If interested please send the request to this email id: [email protected]   

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.